TRACY-1: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. (clinicaltrials.gov) - Oct 7, 2026 - P1/2 | N=64 | Recruiting | Sponsor: RayzeBio, Inc. | Active, not recruiting ➔ Recruiting | N=16 ➔ 64
Enrollment change • Enrollment open • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • SSTR
|